Inventiva (IVA) has released an update.
Inventiva, a biopharmaceutical firm focusing on MASH/NASH treatments, announced its first-half 2024 financials with a cash balance of €10.1 million, after net cash from operations and financing activities. The company issued €20.1 million in royalty certificates for future net sales of its lead candidate, lanifibranor, but also noted no revenues and the necessity to secure additional funds beyond September 2024.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
